Multi-Center Registry Trial of EXCEL Biodegradable Polymer Drug-Eluting Stent
Launched by JW MEDICAL SYSTEMS LTD · May 30, 2006
Trial Information
Current as of June 07, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patient who should be full fill the criteria of using Excel stent.
- • 2. Each included patient should allowed to use Excel stent.
- • 3. Complete revascularization can be achieved through one invasive operation.
- Exclusion Criteria:
- • 1. Patient do not suitable to use Excel stent, for example, not tolerant to anti-platelet drug or undergo cardiac/non-cardiac surgery recently.
- • 2. Patient with multiple branch lesions, thus the single Excel stent cannot resolve the condition.
- • 3. NYH Cardiac functional grading\>3 or Echocardiography LVEF\<0.3.
- • 4. Patient with complete revascularization cannot be resolved by one operation.
About Jw Medical Systems Ltd
JW Medical Systems Ltd. is a pioneering clinical trial sponsor dedicated to advancing medical research and innovation. With a focus on developing cutting-edge therapies and technologies, the company collaborates with healthcare professionals and research institutions to conduct rigorous clinical studies. JW Medical Systems Ltd. is committed to ensuring the highest standards of patient safety and scientific integrity, striving to bring transformative solutions to the healthcare industry and improve patient outcomes globally. Through its comprehensive approach to trial design and execution, the company aims to contribute meaningfully to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Yaling Han, Ph.D.
Principal Investigator
Shenyang Northern Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials